Baseret på 3 - og 5- års humane data fra de kliniske studier var forekomsten af cancer under behandlingen med lasofoxifen ikke højere end for placebo.
Based on 3- and 5-year human data in the clinical trials, the incidence of cancer during treatment with lasofoxifene was not higher than for placebo.